Copyright
©2012 Baishideng Publishing Group Co.
World J Gastroenterol. Sep 21, 2012; 18(35): 4823-4854
Published online Sep 21, 2012. doi: 10.3748/wjg.v18.i35.4823
Published online Sep 21, 2012. doi: 10.3748/wjg.v18.i35.4823
Induce remission (RR of not being in remission) on active therapy | Prevent relapse (RR of relapse) | |
CD | SASP (only 2 RCTs) 0.83 (95%CI: 0.69-1.00; trend) | SASP/5-ASA, ITT analysis, no benefit |
5-ASA 0.91 (95%CI: 0.77-1.06; not significant) | 5-ASA, PP analysis: RR = 0.79 (95%CI: 0.66-0.95; NNT = 13 to prevent relapse) | |
UC | 0.79 (95%CI: 0.73-0.85; NNT = 6) | 0.65 (95%CI: 0.55-0.76; NNT = 4 to prevent relapse) |
- Citation: Thomson AB, Gupta M, Freeman HJ. Use of the tumor necrosis factor-blockers for Crohn's disease. World J Gastroenterol 2012; 18(35): 4823-4854
- URL: https://www.wjgnet.com/1007-9327/full/v18/i35/4823.htm
- DOI: https://dx.doi.org/10.3748/wjg.v18.i35.4823